NCT03197584 2025-02-21
QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
Clinical Trials
8 trialsNCT05145569 2025-01-01
Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer
University of Pittsburgh
Phase 2 Withdrawn
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT04602117 2023-11-18
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
QuantumLeap Healthcare Collaborative
Phase 1 Withdrawn
NCT03400306 2021-12-08
A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer
AbbVie
Phase 1 Withdrawn
NCT03806049 2021-07-15
Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 3 Withdrawn
NCT04561817 2020-10-06
To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Withdrawn
NCT01138137 2017-04-21
N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer
OHSU Knight Cancer Institute
Phase 1 Withdrawn